<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="2865">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 13, 2016</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01470170</url>
  </required_header>
  <id_info>
    <org_study_id>99-1538A3</org_study_id>
    <nct_id>NCT01470170</nct_id>
  </id_info>
  <brief_title>Regimen of Alfentanil in Propofol Sedative Fibro-bronchoscopy</brief_title>
  <official_title>The Optimal Regimen of Alfentanil in Propofol Sedative Fibro-bronchoscopy：a Prospective Randomized, Double-blind, Placebo-controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chang Gung Memorial Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chang Gung Memorial Hospital</source>
  <oversight_info>
    <authority>Taiwan: Department of Health</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Alfentanil (Alf) is used in combination with Propofol (Pro) in fiber-bronchoscopy and in
      many other conscious sedation procedures. Alf and Pro have the characteristic of rapid
      anesthetic onset and quick recovery, synergic sedative effect and unwanted side effects too.
      However, the amount of Alf needed in combination with Pro for induction and the timing of
      administration was no standardized. The investigators designed this study to evaluate the
      optimal regimen, dose and timing of Alf in Target-Controlled infusion (TCI) of Pro for
      flexible bronchoscopy sedation, and also to evaluate the influence of variable regimen of
      Alf and Pro on hypoxemia, hypotension, cough severity, and Pro injection related pain.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Alfentanil (Alf) is used in combination with Propofol (Pro) in fiber-bronchoscopy and in
      many other conscious sedation procedures. Alf and Pro have the characteristic of rapid
      anesthetic onset and quick recovery, synergic sedative effect and unwanted side effects too.
      However, the amount of Alf needed in combination with Pro for induction and the timing of
      administration was no standardized. The investigators designed this study to evaluate the
      optimal regimen, dose and timing of Alf in Target-Controlled infusion (TCI) of Pro for
      flexible bronchoscopy sedation.

      Method: patients will be enrolled and assigned randomly into five groups. In group 1, normal
      saline two minutes before and Alf 2.5μg/kg before Pro were given; In group 2, normal saline
      two minutes before and Alf 5μg/kg before Pro were given; In group 3, Alf 2.5μg/kg two
      minutes before and normal saline before Pro were given; In group 4: Alf 5μg/kg two minutes
      before and normal saline before Pro were given; in group 5, normal saline two minutes and
      before Pro were given.

      Concentration of effect site to loss of consciousness (LOC), dose of Pro to LOC, and
      induction time of variable regimen, as well as hypoxemia, hypotension, cough severity, and
      Pro injection related pain will be recorded and analyzed.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2010</start_date>
  <completion_date type="Actual">December 2011</completion_date>
  <primary_completion_date type="Actual">September 2011</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Effect Site Concentration When Conscious Level Reaches OAAS-3</measure>
    <time_frame>All participants wil be follow for the duration of bronchoscope room stay, an expect average of 2 hours</time_frame>
    <safety_issue>No</safety_issue>
    <description>After the administration of alfentanil and propofol, the effect site concentration was recorded at the time when the consciousness level reaches observer assessment of alertness and sedation scale 3 (OAAS-3). The effect site concentration is the concentration of drug propofol in brain calculated by TCI using Schnider model.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Propofol Dose Needed to Reach Conscious Level OAAS-3</measure>
    <time_frame>All participants wil be follow for the duration of bronchoscope room stay, an expect average of 2 hours</time_frame>
    <safety_issue>No</safety_issue>
    <description>After the administration of Alfentanil and Propofol, the Propofol dose needed to reach conscious level of observer assessment of alertness and sedation scale 3 (OAAS-3) will be recorded.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Induction Time, Time Period That Will be Required for Conscious Level to Reach OAAS-3</measure>
    <time_frame>All participants wil be follow for the duration of bronchoscope room stay, an expect average of 2 hours</time_frame>
    <safety_issue>No</safety_issue>
    <description>After the administration of Alfentanil and Propofol, the time period required to reach conscious level OAAS-3 will be recorded.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Hypoxemia</measure>
    <time_frame>All participants wil be follow for the duration of bronchoscope room stay, an expect average of 2 hours</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Check the frequency of hypoxemia episode during induction, procedure, and recovery time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hypotension</measure>
    <time_frame>All participants wil be follow for the duration of bronchoscope room stay, an expect average of 2 hours</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Check the frequency of hypotension episode during induction, procedure and recovery time</description>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">173</enrollment>
  <condition>Hypoxemia</condition>
  <arm_group>
    <arm_group_label>Group1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Alfentanil 2.5μg/kg before propofol</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Alfentanil 5μg/kg before propofol</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Alfentanil 2.5μg/kg two minutes before propofol</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Alfentanil 5μg/kg two minutes before propofol</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 5 Control</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>propofol alone</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Alfentanil</intervention_name>
    <description>Give Alfentanil before TCI Propofol sedative bronchoscope</description>
    <arm_group_label>Group1</arm_group_label>
    <arm_group_label>Group2</arm_group_label>
    <arm_group_label>Group 3</arm_group_label>
    <arm_group_label>Group 4</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Normal saline</intervention_name>
    <description>Normal Saline (placebo comparator) was given in equivalent amount of alfentanil dosage in each arm, for double blinded purpose.</description>
    <arm_group_label>Group1</arm_group_label>
    <arm_group_label>Group2</arm_group_label>
    <arm_group_label>Group 3</arm_group_label>
    <arm_group_label>Group 4</arm_group_label>
    <arm_group_label>Group 5 Control</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Targeted controlled infusion</intervention_name>
    <description>The Propofol dosage was according to the effect site concentration to reach OAAS-3 ( loss of conscious), using Schneider model</description>
    <arm_group_label>Group1</arm_group_label>
    <arm_group_label>Group2</arm_group_label>
    <arm_group_label>Group 3</arm_group_label>
    <arm_group_label>Group 4</arm_group_label>
    <arm_group_label>Group 5 Control</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Propofol</intervention_name>
    <description>The Propofol dosage is according to the effect site concentration to reach OAAS-3 ( loss of conscious), using TCI Schneider model during the whole procedure of bronchoscope</description>
    <arm_group_label>Group1</arm_group_label>
    <arm_group_label>Group2</arm_group_label>
    <arm_group_label>Group 3</arm_group_label>
    <arm_group_label>Group 4</arm_group_label>
    <arm_group_label>Group 5 Control</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  patients who required elective sedative bronchoscopy

        Exclusion Criteria:

          -  any physical, psychiatric, social problem that avoid from conscious level evaluation,

          -  hypersensitivity or allergy to Propofol, Alfentanil

          -  severe chronic obstructive pulmonary disease (forced expiratory volume in 1 s ,50% of
             predicted value, or requirement for oxygen therapy)

          -  unstable haemodynamic status (defined as a heart rate ＜ 60 or ≧ 120 bpm and/or

          -  a systolic blood pressure (SBP) ＜ 100 or ≧ 180 mmHg)

          -  predictable difficult upper airways (Mallampati classification score of IV)

          -  severe obstructive sleep apnea with apnea hypopnea index (AHI) &gt; 45

          -  Body mass index (BMI) more than 42 in male and 35 in female

          -  renal insufficiency

          -  liver cirrhosis
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Chung Hsing Hsieh, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Chang Gung Memorial Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Chang Gung Memorial Hospital</name>
      <address>
        <city>Taipei</city>
        <zip>333</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Taiwan</country>
  </location_countries>
  <verification_date>August 2015</verification_date>
  <lastchanged_date>August 7, 2015</lastchanged_date>
  <firstreceived_date>October 27, 2011</firstreceived_date>
  <firstreceived_results_date>March 17, 2015</firstreceived_results_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Chang Gung Memorial Hospital</investigator_affiliation>
    <investigator_full_name>Chung-Hsing, Hsieh</investigator_full_name>
    <investigator_title>Chief of Medical Intensive Care Unit, Department of Internal Medicine, Chang-Gung Memorial Hospital, Taipei</investigator_title>
  </responsible_party>
  <keyword>Sedative bronchoscope</keyword>
  <keyword>Alfentanil doses</keyword>
  <keyword>Propofol</keyword>
  <keyword>Targeted controlled infusion</keyword>
  <keyword>Hypoxemia</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Alfentanil</mesh_term>
    <mesh_term>Hypnotics and Sedatives</mesh_term>
    <mesh_term>Propofol</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Group1</title>
          <description>Alfentanil 2.5μg/kg immediately before TCI propofol administration</description>
        </group>
        <group group_id="P2">
          <title>Group2</title>
          <description>Alfentanil 5μg/kg immediately before TCI propofol administration</description>
        </group>
        <group group_id="P3">
          <title>Group 3</title>
          <description>Alfentanil 2.5μg/kg two minutes before TCI propofol administration</description>
        </group>
        <group group_id="P4">
          <title>Group 4</title>
          <description>Alfentanil 5μg/kg two minutes before TCI propofol administration</description>
        </group>
        <group group_id="P5">
          <title>Group 5 Control</title>
          <description>TCI propofol administration alone</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="34"/>
                <participants group_id="P2" count="35"/>
                <participants group_id="P3" count="34"/>
                <participants group_id="P4" count="36"/>
                <participants group_id="P5" count="34"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="34"/>
                <participants group_id="P2" count="35"/>
                <participants group_id="P3" count="34"/>
                <participants group_id="P4" count="36"/>
                <participants group_id="P5" count="34"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Group1</title>
          <description>alfentanil 2.5ug/kg immediately before propofol</description>
        </group>
        <group group_id="B2">
          <title>Group 2</title>
          <description>alfentanil 2.5ug/kg two minutes before propofol</description>
        </group>
        <group group_id="B3">
          <title>Group 3</title>
          <description>alfentanil 5ug/kg immediately before propofol</description>
        </group>
        <group group_id="B4">
          <title>Group 4</title>
          <description>alfentanil 5ug/kg two minutes before propofol</description>
        </group>
        <group group_id="B5">
          <title>Group 5/ Control</title>
          <description>Propofol alone</description>
        </group>
        <group group_id="B6">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <measure_list>
        <measure>
          <title>Number of Participants</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="34"/>
                <measurement group_id="B2" value="35"/>
                <measurement group_id="B3" value="34"/>
                <measurement group_id="B4" value="36"/>
                <measurement group_id="B5" value="34"/>
                <measurement group_id="B6" value="173"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="60.3" spread="11.9"/>
                <measurement group_id="B2" value="60.3" spread="15.8"/>
                <measurement group_id="B3" value="58.8" spread="13.0"/>
                <measurement group_id="B4" value="60.9" spread="13.9"/>
                <measurement group_id="B5" value="62.2" spread="11.1"/>
                <measurement group_id="B6" value="60.5" spread="12.1"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Female</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="15"/>
                <measurement group_id="B2" value="13"/>
                <measurement group_id="B3" value="17"/>
                <measurement group_id="B4" value="12"/>
                <measurement group_id="B5" value="13"/>
                <measurement group_id="B6" value="70"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Male</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="19"/>
                <measurement group_id="B2" value="22"/>
                <measurement group_id="B3" value="17"/>
                <measurement group_id="B4" value="24"/>
                <measurement group_id="B5" value="21"/>
                <measurement group_id="B6" value="103"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Body Mass Index</title>
          <units>kg/m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="23.7" spread="2.4"/>
                <measurement group_id="B2" value="23.5" spread="3.4"/>
                <measurement group_id="B3" value="23.8" spread="4.5"/>
                <measurement group_id="B4" value="23.5" spread="3.3"/>
                <measurement group_id="B5" value="23.2" spread="3.7"/>
                <measurement group_id="B6" value="23.54" spread="3.5"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>American Society of Anaethesiology Physical Status Score</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>1 Normally healthy</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="19"/>
                <measurement group_id="B2" value="23"/>
                <measurement group_id="B3" value="23"/>
                <measurement group_id="B4" value="19"/>
                <measurement group_id="B5" value="24"/>
                <measurement group_id="B6" value="108"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>2 Discrete systemic disease</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="7"/>
                <measurement group_id="B2" value="5"/>
                <measurement group_id="B3" value="7"/>
                <measurement group_id="B4" value="10"/>
                <measurement group_id="B5" value="6"/>
                <measurement group_id="B6" value="35"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>3 Serious, non-incapacitating systemic disease</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="8"/>
                <measurement group_id="B2" value="7"/>
                <measurement group_id="B3" value="4"/>
                <measurement group_id="B4" value="7"/>
                <measurement group_id="B5" value="4"/>
                <measurement group_id="B6" value="30"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Mallampati Score</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>I: soft palate, uvula, fauces, pillars visible</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="4"/>
                <measurement group_id="B2" value="6"/>
                <measurement group_id="B3" value="4"/>
                <measurement group_id="B4" value="5"/>
                <measurement group_id="B5" value="7"/>
                <measurement group_id="B6" value="26"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>II: soft palate, uvula, fauces visible</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="16"/>
                <measurement group_id="B2" value="13"/>
                <measurement group_id="B3" value="14"/>
                <measurement group_id="B4" value="10"/>
                <measurement group_id="B5" value="12"/>
                <measurement group_id="B6" value="65"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>III: soft palate, base of uvula visible</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="14"/>
                <measurement group_id="B2" value="16"/>
                <measurement group_id="B3" value="16"/>
                <measurement group_id="B4" value="21"/>
                <measurement group_id="B5" value="15"/>
                <measurement group_id="B6" value="82"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Regular use of opioid</title>
          <description>use of opioid related medication for more than 5 days per week</description>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="1"/>
                <measurement group_id="B2" value="1"/>
                <measurement group_id="B3" value="1"/>
                <measurement group_id="B4" value="0"/>
                <measurement group_id="B5" value="0"/>
                <measurement group_id="B6" value="3"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Regular use of sedation drugs</title>
          <description>use of sleeping pill or sedative medication for more than 5 days per week</description>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="3"/>
                <measurement group_id="B2" value="2"/>
                <measurement group_id="B3" value="4"/>
                <measurement group_id="B4" value="5"/>
                <measurement group_id="B5" value="3"/>
                <measurement group_id="B6" value="17"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Alcohol use</title>
          <description>alcohol drinking for more than 5 days per week</description>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="3"/>
                <measurement group_id="B2" value="4"/>
                <measurement group_id="B3" value="1"/>
                <measurement group_id="B4" value="5"/>
                <measurement group_id="B5" value="4"/>
                <measurement group_id="B6" value="17"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>smoking status</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>never</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="20"/>
                <measurement group_id="B2" value="18"/>
                <measurement group_id="B3" value="21"/>
                <measurement group_id="B4" value="19"/>
                <measurement group_id="B5" value="20"/>
                <measurement group_id="B6" value="98"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>current</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="7"/>
                <measurement group_id="B2" value="12"/>
                <measurement group_id="B3" value="8"/>
                <measurement group_id="B4" value="11"/>
                <measurement group_id="B5" value="6"/>
                <measurement group_id="B6" value="44"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>ex-</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="7"/>
                <measurement group_id="B2" value="5"/>
                <measurement group_id="B3" value="5"/>
                <measurement group_id="B4" value="6"/>
                <measurement group_id="B5" value="8"/>
                <measurement group_id="B6" value="31"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>heart rate</title>
          <units>beats/min</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="80.3" spread="15.5"/>
                <measurement group_id="B2" value="78.1" spread="12.6"/>
                <measurement group_id="B3" value="73.9" spread="14.2"/>
                <measurement group_id="B4" value="80.3" spread="14.5"/>
                <measurement group_id="B5" value="80.2" spread="11.4"/>
                <measurement group_id="B6" value="78.6" spread="14.4"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>SBP</title>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="147.1" spread="24.3"/>
                <measurement group_id="B2" value="139.9" spread="20.5"/>
                <measurement group_id="B3" value="139.2" spread="20.8"/>
                <measurement group_id="B4" value="142.4" spread="21.5"/>
                <measurement group_id="B5" value="145.8" spread="20.5"/>
                <measurement group_id="B6" value="142.9" spread="21.5"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>DBP</title>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="80.8" spread="12.7"/>
                <measurement group_id="B2" value="78.7" spread="13.5"/>
                <measurement group_id="B3" value="76.9" spread="11.8"/>
                <measurement group_id="B4" value="79.5" spread="12.1"/>
                <measurement group_id="B5" value="80.2" spread="11.4"/>
                <measurement group_id="B6" value="79.2" spread="12.2"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>SpO2</title>
          <units>percentage of saturation</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="98.8" spread="1.5"/>
                <measurement group_id="B2" value="98.6" spread="1.5"/>
                <measurement group_id="B3" value="99.0" spread="1.4"/>
                <measurement group_id="B4" value="99.2" spread="1.3"/>
                <measurement group_id="B5" value="99.1" spread="1.5"/>
                <measurement group_id="B6" value="98.9" spread="1.4"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Effect Site Concentration When Conscious Level Reaches OAAS-3</title>
        <description>After the administration of alfentanil and propofol, the effect site concentration was recorded at the time when the consciousness level reaches observer assessment of alertness and sedation scale 3 (OAAS-3). The effect site concentration is the concentration of drug propofol in brain calculated by TCI using Schnider model.</description>
        <time_frame>All participants wil be follow for the duration of bronchoscope room stay, an expect average of 2 hours</time_frame>
        <safety_issue>No</safety_issue>
        <group_list>
          <group group_id="O1">
            <title>Group1</title>
            <description>alfentanil 2.5ug/kg immediately before propofol</description>
          </group>
          <group group_id="O2">
            <title>Group 2</title>
            <description>alfentanil 2.5ug/kg two minutes before propofol</description>
          </group>
          <group group_id="O3">
            <title>Group 3</title>
            <description>alfentanil 5ug/kg immediately before propofol</description>
          </group>
          <group group_id="O4">
            <title>Group 4</title>
            <description>alfentanil 5ug/kg two minutes before propofol</description>
          </group>
          <group group_id="O5">
            <title>Group 5 /Control</title>
            <description>Propofol alone</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="34"/>
                  <measurement group_id="O2" value="35"/>
                  <measurement group_id="O3" value="34"/>
                  <measurement group_id="O4" value="36"/>
                  <measurement group_id="O5" value="34"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Effect Site Concentration When Conscious Level Reaches OAAS-3</title>
            <description>After the administration of alfentanil and propofol, the effect site concentration was recorded at the time when the consciousness level reaches observer assessment of alertness and sedation scale 3 (OAAS-3). The effect site concentration is the concentration of drug propofol in brain calculated by TCI using Schnider model.</description>
            <units>ug/ml</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="2.3" spread="0.4"/>
                  <measurement group_id="O2" value="2.2" spread="0.4"/>
                  <measurement group_id="O3" value="2.5" spread="0.4"/>
                  <measurement group_id="O4" value="2.2" spread="0.5"/>
                  <measurement group_id="O5" value="2.6" spread="0.4"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Propofol Dose Needed to Reach Conscious Level OAAS-3</title>
        <description>After the administration of Alfentanil and Propofol, the Propofol dose needed to reach conscious level of observer assessment of alertness and sedation scale 3 (OAAS-3) will be recorded.</description>
        <time_frame>All participants wil be follow for the duration of bronchoscope room stay, an expect average of 2 hours</time_frame>
        <safety_issue>No</safety_issue>
        <group_list>
          <group group_id="O1">
            <title>Group1</title>
            <description>alfentanil 2.5ug/kg immediately before propofol</description>
          </group>
          <group group_id="O2">
            <title>Group 2</title>
            <description>alfentanil 2.5ug/kg two minutes before propofol</description>
          </group>
          <group group_id="O3">
            <title>Group 3</title>
            <description>alfentanil 5ug/kg immediately before propofol</description>
          </group>
          <group group_id="O4">
            <title>Group 4</title>
            <description>alfentanil 5ug/kg two minutes before propofol</description>
          </group>
          <group group_id="O5">
            <title>Group 5 /Control</title>
            <description>Propofol alone</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="34"/>
                  <measurement group_id="O2" value="35"/>
                  <measurement group_id="O3" value="34"/>
                  <measurement group_id="O4" value="36"/>
                  <measurement group_id="O5" value="34"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Propofol Dose Needed to Reach Conscious Level OAAS-3</title>
            <description>After the administration of Alfentanil and Propofol, the Propofol dose needed to reach conscious level of observer assessment of alertness and sedation scale 3 (OAAS-3) will be recorded.</description>
            <units>mg</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="67.8" spread="56.2"/>
                  <measurement group_id="O2" value="56.4" spread="29.2"/>
                  <measurement group_id="O3" value="75.3" spread="37.1"/>
                  <measurement group_id="O4" value="54.8" spread="29.0"/>
                  <measurement group_id="O5" value="76.3" spread="31.9"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Induction Time, Time Period That Will be Required for Conscious Level to Reach OAAS-3</title>
        <description>After the administration of Alfentanil and Propofol, the time period required to reach conscious level OAAS-3 will be recorded.</description>
        <time_frame>All participants wil be follow for the duration of bronchoscope room stay, an expect average of 2 hours</time_frame>
        <safety_issue>No</safety_issue>
        <group_list>
          <group group_id="O1">
            <title>Group1</title>
            <description>alfentanil 2.5ug/kg immediately before propofol</description>
          </group>
          <group group_id="O2">
            <title>Group 2</title>
            <description>alfentanil 2.5ug/kg two minutes before propofol</description>
          </group>
          <group group_id="O3">
            <title>Group 3</title>
            <description>alfentanil 5ug/kg immediately before propofol</description>
          </group>
          <group group_id="O4">
            <title>Group 4</title>
            <description>alfentanil 5ug/kg two minutes before propofol</description>
          </group>
          <group group_id="O5">
            <title>Group 5 /Control</title>
            <description>Propofol alone</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="34"/>
                  <measurement group_id="O2" value="35"/>
                  <measurement group_id="O3" value="34"/>
                  <measurement group_id="O4" value="36"/>
                  <measurement group_id="O5" value="34"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Induction Time, Time Period That Will be Required for Conscious Level to Reach OAAS-3</title>
            <description>After the administration of Alfentanil and Propofol, the time period required to reach conscious level OAAS-3 will be recorded.</description>
            <units>second</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="279" spread="189"/>
                  <measurement group_id="O2" value="263" spread="170"/>
                  <measurement group_id="O3" value="374" spread="203"/>
                  <measurement group_id="O4" value="247" spread="183"/>
                  <measurement group_id="O5" value="402" spread="190"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Hypoxemia</title>
        <description>Check the frequency of hypoxemia episode during induction, procedure, and recovery time</description>
        <time_frame>All participants wil be follow for the duration of bronchoscope room stay, an expect average of 2 hours</time_frame>
        <safety_issue>Yes</safety_issue>
        <group_list>
          <group group_id="O1">
            <title>Group1</title>
            <description>alfentanil 2.5ug/kg immediately before propofol</description>
          </group>
          <group group_id="O2">
            <title>Group 2</title>
            <description>alfentanil 2.5ug/kg two minutes before propofol</description>
          </group>
          <group group_id="O3">
            <title>Group 3</title>
            <description>alfentanil 5ug/kg immediately before propofol</description>
          </group>
          <group group_id="O4">
            <title>Group 4</title>
            <description>alfentanil 5ug/kg two minutes before propofol</description>
          </group>
          <group group_id="O5">
            <title>Group 5 /Control</title>
            <description>Propofol alone</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="34"/>
                  <measurement group_id="O2" value="35"/>
                  <measurement group_id="O3" value="34"/>
                  <measurement group_id="O4" value="36"/>
                  <measurement group_id="O5" value="34"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Hypoxemia</title>
            <description>Check the frequency of hypoxemia episode during induction, procedure, and recovery time</description>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>Induction time</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                  <measurement group_id="O2" value="9"/>
                  <measurement group_id="O3" value="1"/>
                  <measurement group_id="O4" value="6"/>
                  <measurement group_id="O5" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Procedure time</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="13"/>
                  <measurement group_id="O2" value="10"/>
                  <measurement group_id="O3" value="16"/>
                  <measurement group_id="O4" value="15"/>
                  <measurement group_id="O5" value="18"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Recovery time</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="5"/>
                  <measurement group_id="O2" value="2"/>
                  <measurement group_id="O3" value="5"/>
                  <measurement group_id="O4" value="4"/>
                  <measurement group_id="O5" value="5"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Hypotension</title>
        <description>Check the frequency of hypotension episode during induction, procedure and recovery time</description>
        <time_frame>All participants wil be follow for the duration of bronchoscope room stay, an expect average of 2 hours</time_frame>
        <safety_issue>Yes</safety_issue>
        <group_list>
          <group group_id="O1">
            <title>Group1</title>
            <description>alfentanil 2.5ug/kg immediately before propofol</description>
          </group>
          <group group_id="O2">
            <title>Group 2</title>
            <description>alfentanil 2.5ug/kg two minutes before propofol</description>
          </group>
          <group group_id="O3">
            <title>Group 3</title>
            <description>alfentanil 5ug/kg immediately before propofol</description>
          </group>
          <group group_id="O4">
            <title>Group 4</title>
            <description>alfentanil 5ug/kg two minutes before propofol</description>
          </group>
          <group group_id="O5">
            <title>Group 5 /Control</title>
            <description>Propofol alone</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="34"/>
                  <measurement group_id="O2" value="35"/>
                  <measurement group_id="O3" value="34"/>
                  <measurement group_id="O4" value="36"/>
                  <measurement group_id="O5" value="34"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Hypotension</title>
            <description>Check the frequency of hypotension episode during induction, procedure and recovery time</description>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>Induction time</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="2"/>
                  <measurement group_id="O2" value="1"/>
                  <measurement group_id="O3" value="0"/>
                  <measurement group_id="O4" value="0"/>
                  <measurement group_id="O5" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Procedure time</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="7"/>
                  <measurement group_id="O2" value="7"/>
                  <measurement group_id="O3" value="11"/>
                  <measurement group_id="O4" value="5"/>
                  <measurement group_id="O5" value="6"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Recovery time</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="4"/>
                  <measurement group_id="O2" value="4"/>
                  <measurement group_id="O3" value="4"/>
                  <measurement group_id="O4" value="2"/>
                  <measurement group_id="O5" value="4"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Before, during, and after the fibro-bronchoscopy procedure</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Group1</title>
          <description>alfentanil 2.5ug/kg immediately before propofol</description>
        </group>
        <group group_id="E2">
          <title>Group 2</title>
          <description>alfentanil 2.5ug/kg two minutes before propofol</description>
        </group>
        <group group_id="E3">
          <title>Group 3</title>
          <description>alfentanil 5ug/kg immediately before propofol</description>
        </group>
        <group group_id="E4">
          <title>Group 4</title>
          <description>alfentanil 5ug/kg two minutes before propofol</description>
        </group>
        <group group_id="E5">
          <title>Group 5 /Control</title>
          <description>Propofol alone</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="34"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="34"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Yu-Lun, Lo</name_or_title>
      <organization>Department of Thoracic Medicine</organization>
      <phone>+886-3-3281200 ext 5108</phone>
      <email>loyulun@hotmail.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>
